{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:05:20Z","timestamp":1776413120194,"version":"3.51.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurgie"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Seit nunmehr 10\u00a0Jahren stehen Medikamente auf der Basis anorektischer Peptidhormone zur Behandlung der Adipositas (OMM) zur Verf\u00fcgung. In dieser \u00dcbersichtsarbeit wird die Evidenz zu den 3 beh\u00f6rdlich zugelassenen und am h\u00e4ufigsten verwendeten Medikamenten (Liraglutid, Semaglutid und Tirzepatid) dargestellt. In diesem Kontext wurde innerhalb des SCALE-Programms (Liraglutid), des STEP-Programm (Semaglutid) und des SURMOUNT-Programms (Tirzepatid) eine Vielzahl von hochwertigen placebokontrollierten prospektiv randomisierten Studien durchgef\u00fchrt. Demnach liegt der Wirkungsgrad auf die mittlere Gewichtsabnahme f\u00fcr Liraglutid bei 6\u20138\u202f%, f\u00fcr Semaglutid bei 9,6\u201315\u202f% und f\u00fcr Tirzepatid bei 14,7\u201322,1\u202f%. Ebenso zeigen die Medikamente einen hohen antidiabetischen Wirkungsgrad, wobei die erreichte Gewichtsabnahme bei Diabetikern meist geringer ist. Insgesamt sind die Sicherheit und Vertr\u00e4glichkeit der 3\u00a0Medikamente hoch. Die h\u00e4ufigsten unerw\u00fcnschten Ereignisse treten meist fr\u00fch w\u00e4hrend der Behandlung auf und klingen mit der Zeit ab. Die positiven Effekte werden durch ein Absetzen der Therapie meist nivelliert. Bez\u00fcglich harter Endpunkte konnte die SELECT-Studie f\u00fcr schwere unerw\u00fcnschte kardiovaskul\u00e4re Ereignisse (MACE) eine Risikoreduktion von 20\u202f% unter Semaglutid zeigen. Daten zu weiteren harten Endpunkten und zum Langzeitverlauf existieren bisher nicht.<\/jats:p>","DOI":"10.1007\/s00104-025-02402-z","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:11:00Z","timestamp":1762355460000},"page":"11-20","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peptidhormonanaloga basierte medikament\u00f6se Adipositastherapie ist effektiv","Peptide hormone analogue-based pharmacotherapy for obesity is effective"],"prefix":"10.1007","volume":"97","author":[{"given":"Muzamil","family":"Hussain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Dimitry","family":"Miras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"1","key":"2402_CR1","doi-asserted-by":"publisher","first-page":"e2457232","DOI":"10.1001\/jamanetworkopen.2024.57232","volume":"8","author":"P Berning","year":"2025","unstructured":"Berning\u00a0P et\u00a0al (2025) Longitudinal analysis of obesity drug use and public awareness. JAMA Network Open 8(1):e2457232\u2013e2457232","journal-title":"JAMA Network Open"},{"issue":"10431","key":"2402_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"NH Phelps","year":"2024","unstructured":"Phelps\u00a0NH et\u00a0al (2024) Worldwide trends in underweight and obesity from 1990 to 2022: a\u00a0pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403(10431):1027\u20131050","journal-title":"Lancet"},{"key":"2402_CR3","doi-asserted-by":"crossref","unstructured":"Tan SCW et\u00a0al (2025) Global Burden of Cardiovascular Diseases and its Risk Factors, 1990\u20132021: A\u00a0Systematic Analysis for the Global Burden of Disease Study 2021. QJM: hcaf22","DOI":"10.1093\/qjmed\/hcaf022"},{"issue":"3","key":"2402_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino\u00a0F et\u00a0al (2025) Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 13(3):221\u2013262","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2402_CR5","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","volume":"30","author":"L Busetto","year":"2024","unstructured":"Busetto\u00a0L et\u00a0al (2024) A\u00a0new framework for the diagnosis, staging and management of obesity in adults. Nat Med 30(9):2395\u20132399","journal-title":"Nat Med"},{"issue":"1","key":"2402_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer\u00a0X et\u00a0al (2015) A\u00a0randomized, controlled trial of 3.0\u202fmg of liraglutide in weight management. N\u00a0Engl J Med 373(1):11\u201322","journal-title":"N Engl J Med"},{"issue":"7","key":"2402_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies\u00a0MJ et\u00a0al (2015) Efficacy of liraglutide for weight loss among patients with type\u00a02 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314(7):687\u2013699","journal-title":"JAMA"},{"issue":"5","key":"2402_CR8","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2337\/dc19-1745","volume":"43","author":"WT Garvey","year":"2020","unstructured":"Garvey\u00a0WT et\u00a0al (2020) Efficacy and safety of liraglutide 3.0\u202fmg in individuals with overweight or obesity and type\u00a02 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care 43(5):1085\u20131093","journal-title":"Diabetes Care"},{"issue":"8","key":"2402_CR9","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman\u00a0A et\u00a0al (2016) Effect of liraglutide 3.0\u202fmg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes Relat Metab Disord 40(8):1310\u20131319","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"11","key":"2402_CR10","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden\u00a0TA et\u00a0al (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes Relat Metab Disord 37(11):1443\u20131451","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"11","key":"2402_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JP Wilding","year":"2021","unstructured":"Wilding\u00a0JP et\u00a0al (2021) Once-weekly semaglutide in adults with overweight or obesity. N\u00a0Engl J Med 384(11):989\u20131002","journal-title":"N Engl J Med"},{"issue":"8","key":"2402_CR12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JP Wilding","year":"2022","unstructured":"Wilding\u00a0JP et\u00a0al (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1\u00a0trial extension. Diabetes Obesity Metabolism 24(8):1553\u20131564","journal-title":"Diabetes Obesity Metabolism"},{"issue":"14","key":"2402_CR13","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino\u00a0D et\u00a0al (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325(14):1414\u20131425","journal-title":"JAMA"},{"issue":"10278","key":"2402_CR14","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies\u00a0M et\u00a0al (2021) Semaglutide 2\u00b7 4\u202fmg once a\u00a0week in adults with overweight or obesity, and type\u00a02 diabetes (STEP\u00a02): a\u00a0randomised, double-blind, double-dummy, placebo-controlled, phase\u00a03\u00a0trial. Lancet 397(10278):971\u2013984","journal-title":"Lancet"},{"issue":"3","key":"2402_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki\u00a0T et\u00a0al (2022) Semaglutide once a\u00a0week in adults with overweight or obesity, with or without type\u00a02 diabetes in an east Asian population (STEP\u00a06): a\u00a0randomised, double-blind, double-dummy, placebo-controlled, phase\u00a03a\u00a0trial. Lancet Diabetes Endocrinol 10(3):193\u2013206","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2402_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","volume":"12","author":"Y Mu","year":"2024","unstructured":"Mu\u00a0Y et\u00a0al (2024) Efficacy and safety of once weekly semaglutide 2\u00b7 4\u202fmg for weight management in a\u00a0predominantly east Asian population with overweight or obesity (STEP\u00a07): a\u00a0double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 12(3):184\u2013195","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"2402_CR17","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden\u00a0TA et\u00a0al (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 325(14):1403\u20131413","journal-title":"JAMA"},{"issue":"10","key":"2402_CR18","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey\u00a0WT et\u00a0al (2022) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5\u00a0trial. Nat Med 28(10):2083\u20132091","journal-title":"Nat Med"},{"issue":"2","key":"2402_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino\u00a0DM et\u00a0al (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 327(2):138\u2013150","journal-title":"JAMA"},{"issue":"17","key":"2402_CR20","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal\u00a0H et\u00a0al (2024) Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N\u00a0Engl J Med 391(17):1573\u20131583","journal-title":"N Engl J Med"},{"issue":"9","key":"2402_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"McGowan\u00a0BM et\u00a0al (2024) Efficacy and safety of once-weekly semaglutide 2\u00b7 4\u202fmg versus placebo in people with obesity and prediabetes (STEP\u00a010): a\u00a0randomised, double-blind, placebo-controlled, multicentre phase\u00a03\u00a0trial. Lancet Diabetes Endocrinol 12(9):631\u2013642","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2402_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff\u00a0AM et\u00a0al (2022) Tirzepatide once weekly for the treatment of obesity. N\u00a0Engl J Med 387(3):205\u2013216","journal-title":"N Engl J Med"},{"issue":"10","key":"2402_CR23","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff\u00a0AM et\u00a0al (2025) Tirzepatide for obesity treatment and diabetes prevention. N\u00a0Engl J Med 392(10):958\u2013971","journal-title":"N Engl J Med"},{"issue":"5","key":"2402_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2213-8587(24)00377-2","volume":"13","author":"T Kadowaki","year":"2025","unstructured":"Kadowaki\u00a0T et\u00a0al (2025) Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a\u00a0multicentre, randomised, double-blind, placebo-controlled phase\u00a03\u00a0trial. Lancet Diabetes Endocrinol 13(5):384\u2013396","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10402","key":"2402_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey\u00a0WT et\u00a0al (2023) Tirzepatide once weekly for the treatment of obesity in people with type\u00a02 diabetes (SURMOUNT-2): a\u00a0double-blind, randomised, multicentre, placebo-controlled, phase\u00a03\u00a0trial. Lancet 402(10402):613\u2013626","journal-title":"Lancet"},{"issue":"11","key":"2402_CR26","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden\u00a0TA et\u00a0al (2023) Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT\u20113 phase\u00a03\u00a0trial. Nat Med 29(11):2909\u20132918","journal-title":"Nat Med"},{"issue":"1","key":"2402_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne\u00a0LJ et\u00a0al (2024) Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT\u20114 randomized clinical trial. JAMA 331(1):38\u201348","journal-title":"JAMA"},{"key":"2402_CR28","doi-asserted-by":"crossref","unstructured":"Aronne LJ et\u00a0al (2025) Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N\u00a0Engl J Med","DOI":"10.1056\/NEJMoa2416394"},{"issue":"24","key":"2402_CR29","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff\u00a0AM et\u00a0al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N\u00a0Engl J Med 389(24):2221\u20132232","journal-title":"N Engl J Med"},{"issue":"11","key":"2402_CR30","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","volume":"184","author":"TA Wadden","year":"2024","unstructured":"Wadden\u00a0TA et\u00a0al (2024) Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5\u00a0trials. JAMA Intern Med 184(11):1290\u20131300","journal-title":"JAMA Intern Med"},{"key":"2402_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03893-3","author":"H Gasoyan","year":"2025","unstructured":"Gasoyan\u00a0H, Alavi\u00a0MH, Zajichek\u00a0A, Casacchia\u00a0NJ, Al Jabri\u00a0A, Bena\u00a0J, Feng\u00a0X, Wilson\u00a0R, Corcelles\u00a0R, Butsch\u00a0WS, Singh\u00a0RP, Das\u00a0N, Jeong\u00a0H, Mentias\u00a0A, Tang\u00a0WHW, Burguera\u00a0B, Rosenthal\u00a0RJ, Nissen\u00a0SE, Rothberg\u00a0MB, Aminian\u00a0A (2025) Macrovascular and microvascular outcomes of metabolic surgery versus GLP\u20111 receptor agonists in patients with diabetes and obesity. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03893-3","journal-title":"Nat Med"}],"container-title":["Die Chirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-025-02402-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-025-02402-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-025-02402-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:24:19Z","timestamp":1768407859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-025-02402-z"}},"subtitle":["Was ist die Evidenz zu harten Endpunkten und zum Langzeitverlauf?","What is the evidence on hard end points and the long-term course?"],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2402"],"URL":"https:\/\/doi.org\/10.1007\/s00104-025-02402-z","relation":{},"ISSN":["2731-6971","2731-698X"],"issn-type":[{"value":"2731-6971","type":"print"},{"value":"2731-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Hussain hat von Breakthrough T1D (ehemals JDRF) ein Forschungsstipendium f\u00fcr seine Einrichtung erhalten, das auch ein Stipendium f\u00fcr klinische Forschung umfasst. A.D.\u00a0Miras hat Forschungsgelder vom MRC, NIHR, der Jon Moulton Charitable Foundation, Anabio, Fractyl, Boehringer Ingelheim, Gila, Randox und Novo Nordisk erhalten. ADM hat Honorare f\u00fcr Vortr\u00e4ge und Pr\u00e4sentationen von Novo Nordisk, AstraZeneca, Currax Pharmaceuticals, Boehringer Ingelheim, Screen Health, GI Dynamics, Algorithm, Eli Lilly, Ethicon und Medtronic erhalten. ADM und Prof. Dr. Carel le Roux sind Anteilseigner der Beyond BMI-Klinik, die klinische Adipositasbehandlungen anbietet.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}